American Society of Hematology

How is frontline immunosuppressive therapy for aplastic anemia evolving in 2026?

Join the next Aplastic Anemia Clinical Case Webinar focusing on highlights from and practical, evidence-based strategies for patient management.

🗓️ June 18 | 🕕 6–7 p.m.
Register now: https://ow.ly/KLqh50ZbioQ

The House Appropriations Committee has advanced the FY 2027 Labor, Health and Human Services, Education bill, which funds the NIH and other critical research and public health programs.

For the hematology community, robust investment at the NIH is essential to drive innovation toward cures and treatment of blood diseases such as sickle cell disease, leukemia, and other blood-related diseases. While the bill includes an increase for NIH and rejects several of the most severe proposed cuts, the NIH increase does not keep up with biomedical research inflation and it still proposes reductions to public health programs, including at the CDC.

Sustained and strengthened investments are critical to ensure progress continues for patients who depend on these advances.

As Congress considers next steps, we urge ASH members to take immediate action in the . Contact your Members of Congress and urge them to advance this funding bill with stronger investment levels and reject harmful proposed policies.

Take action TODAY: https://ow.ly/7UlW50ZbaLf

Si desea postular al CRTI-LA, el mejor momento para comenzar es hoy. 🚀

La aplicación incluye algunos pasos, como:
✔️ Preparar su CV
✔️ Desarrollar una propuesta de investigación
✔️ Organizar documentos y referencias

No deje todo para el último momento.

📍 Santiago, Chile | Abril 2027
⚠️ Inscripciones abiertas hasta el 24 de junio de 2026.

Conozca más e inscríbase. https://ow.ly/SzM650Z9yej

Two new studies examining whether the time of day of CAR-T infusion influences outcomes in relapsed/refractory large B-cell lymphoma arrive at divergent conclusions — illustrating both biologic plausibility and methodological fragility. Read more about the future of cancer chronotherapy in The Hematologist: https://ow.ly/QQzO50Z5yFM

What happens to sickle hemoglobin after red blood cells break down, and how does it contribute to liver damage?

Join this month’s Journal Club to:

▪️ Learn how liver sinusoidal endothelial cells help clear extracellular sickle hemoglobin

▪️ Explore the cellular pathways involved in hemoglobin uptake and processing

▪️ Discuss the therapeutic implications for sickle cell disease and related hemolytic disorders

Register now: https://ow.ly/9s6350Z9QAq

Blood Journals Portfolio

📢 Reminder: ASH CRTI applications are open!

Fellows and early- to mid-career faculty across Latin America, Asia-Pacific, Mediterranean, Middle East, and North Africa are invited to apply for this interactive in-person training program focused on advancing clinical research skills.

Participants will gain:

🔬 Practical training in clinical trial design and ex*****on

🧬 Skills in patient-oriented and translational research

🤝 Access to mentorship, peer collaboration, and global networking

📊 Guidance in developing a research project



Deadline: June 24, 2026 by 11:59 PM Eastern Time

Apply now: https://ow.ly/r2Am50Z9xOI

⏳ 2 weeks left to apply for our TRTH 2027 cohort!
The Translational Research Training in Hematology (TRTH) program offers a unique, year-long training and mentoring experience designed to help early-career researchers build a strong path in translational science.

You’ll gain direct feedback on your own research project, connect with leading experts, and become part of an international network that supports you well beyond the program.

📅 Submit your application by 15:00 (CET) on June 18, 2026: https://ow.ly/2pO850Z86OW

Will you be at ? Be sure to stop by the ASH Booth (A4.05)!

Meet the ASH team, explore resources, and meet the Blood Journals editors for one-on-one discussions about submissions, journal scope, and publishing in hematology.

Also, don't miss the EHA-ASH Joint Symposium on June 12, from 3:30 p.m. - 4:30 p.m. Local time.

See you there! 🩸

As treatment options for sickle cell disease continue to expand, understanding how clinical outcomes compare with treatment costs is increasingly important.

New research published in Blood found that stem cell transplantation was the most cost-effective treatment option for adults living with sickle cell disease when compared with gene therapy and standard of care.

Read the press release for more: https://ow.ly/rPnh50Z7aR4

Blood Journals Portfolio

Your research could shape future discoveries, influence care of patients, or redefine what comes next in hematology. Present it at the 68th ASH Annual Meeting and Exposition.

Abstract submissions for are now open. Share your work with a global community of hematology professionals and contribute to the conversations driving the field forward.

🗓️ Submit by August 4 at 11:59 p.m. Pacific time.

🔗 https://ow.ly/j1KV50Z6EYs